P07 SHOULD PATIENTS UNDERGOING RENAL TRANSPLANT WITHOUT INDUCTION WITH BIOLOGIC AGENTS, RECEIVE CYTOMEGALOVIRUS CHEMOPROPHYLAXIS?
D. Rangaswamy, S. Kaza, S. Nagaraju and 1 more
Kidney International Reports · 2016
doi:10.1016/j.ekir.2016.09.013 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Cytomegalovirus (CMV) is a frequently encountered opportunistic pathogen in renal transplant recipients (RTR). Spectrum of CMV infection ranges from latent infection to life-threatening multisystem disease. Current KDIGO guidelines recommend RTR to receive a biologic induction agent and all RTR (except in D-/R- CMV serology) to receive chemoprophylaxis for CMV infection with oral ganciclovir or valganciclovir for at least 3 months post transplantation. Currently no guidelines exist for use of CMV prophylaxis in patients transplanted without a biologic induction.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.